Profile data is unavailable for this security.
About the company
Zhejiang Medicine Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals and life nutrition products, as well as pharmaceutical distribution business. The pharmaceutical business includes pharmaceutical manufacturing products and pharmaceutical commerce. Pharmaceutical manufacturing products mainly include pharmaceutical raw materials such as anti-resistant antibiotics and anti-malarial products, pharmaceutical preparations such as hypoglycemic and hormone products, and health products such as lutein. Pharmaceutical commerce is mainly engaged in the distribution of winning bids. Life nutrition products are mainly vitamins and vitamin-like products such as synthetic vitamin E, vitamin A, natural vitamin E, vitamin H (biotin), vitamin D3 and others. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in CNY (TTM)8.96bn
- Net income in CNY1.24bn
- Incorporated1997
- Employees5.82k
- LocationZhejiang Medicine Co LtdNo. 168 Zhiyuanzhong AvenueBinhai XinchengSHAOXING 312366ChinaCHN
- Phone+86 57 585211969
- Fax+86 57 585211976
- Websitehttps://www.zmc.top/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical Holding Co | 2.72bn | 981.20m | 13.59bn | 596.00 | 13.86 | 3.83 | -- | 5.00 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 9.26bn | 930.27m | 14.31bn | 11.47k | 15.38 | 1.05 | -- | 1.54 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
| Zhejiang Medicine Co Ltd | 8.96bn | 1.24bn | 14.40bn | 5.82k | 11.57 | 1.30 | -- | 1.61 | 1.29 | 1.29 | 9.31 | 11.50 | 0.6499 | 2.76 | 5.65 | 1,540,449.00 | 8.19 | 5.31 | 10.15 | 6.93 | 39.47 | 36.97 | 12.60 | 7.68 | 2.01 | -- | 0.0784 | 30.91 | 20.29 | 5.88 | 170.11 | 27.62 | 3.74 | -18.03 |
| Guobang Pharma Ltd | 5.94bn | 872.95m | 15.05bn | 4.00k | 17.16 | 1.82 | -- | 2.53 | 1.57 | 1.57 | 10.68 | 14.80 | 0.5603 | 3.06 | 7.04 | 1,484,531.00 | 8.20 | 9.52 | 10.33 | 12.47 | 24.67 | 27.10 | 14.64 | 14.91 | 2.30 | -- | 0.1038 | 24.76 | 10.12 | 9.15 | 27.61 | 19.94 | -7.08 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 2.71bn | 294.90m | 15.08bn | 3.58k | 50.92 | 4.84 | -- | 5.56 | 1.40 | 1.40 | 12.85 | 14.67 | 0.504 | 1.10 | 3.98 | 757,880.40 | 5.37 | 5.94 | 7.32 | 7.80 | 48.93 | 45.09 | 10.66 | 11.74 | 1.46 | 7.54 | 0.4102 | 16.95 | 20.75 | 40.89 | 58.17 | 22.38 | 71.42 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Sep 2024 | 7.73m | 0.81% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 6.85m | 0.72% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 6.33m | 0.66% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 3.94m | 0.41% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 2.86m | 0.30% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.44m | 0.25% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 1.79m | 0.19% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.21m | 0.13% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.15m | 0.12% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 936.20k | 0.10% |
